← All trials
NCT06063473
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2023
- Primary completion
- Jul 13, 2023
- Completion date
- Jul 13, 2023
- First posted
- Oct 2, 2023
- Last posted
- Oct 2, 2023
- Enrollment
- 762
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taro PharmaceuticalsLead sponsor
- Taro PharmaceuticalsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.